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Background: The Wnt/β-catenin signalling is aberrantly activated in primary B cell chronic lymphocytic leukaemia
(CLL). Epigenetic silencing of pathway inhibitor genes may be a mechanism for its activation. In this study,
we investigated systematically and quantitatively the methylation status of 12 Wnt/β-catenin pathway inhibitor
genes – CDH1, DACT1, DKK1, DKK2, DKK3, DKK4, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5 and WIF1 – in the cell lines EHEB
and MEC-1 as well as patient samples.
Methods: Quantification of DNA methylation was performed by means of bisulphite pyrosequencing and
confirmed by bisulphite Sanger sequencing. Gene expression was analysed by qPCR using GAPDH as internal
control. E-cadherin and β-catenin protein quantification was carried out by microsphere-based immunoassays.
Methylation differences observed between the patient and control groups were tested using generalised least
squares models.
Results: For 10 genes, a higher methylation level was observed in tumour material. Only DKK4 exhibited similarly
high methylation levels in both tumour and normal specimens, while DACT1 was always essentially unmethylated.
However, also for these inhibitors, treatment of cells with the demethylating agent 5-aza-2´-deoxycytidine resulted
in an induction of their expression, as shown by quantitative PCR, suggesting an indirect epigenetic control of
activity. While the degree of demethylation and its transcriptional consequences differed between the genes, there
was an overall high correlation of demethylation and increased activity. Protein expression studies revealed that no
constitutive Wnt/β-catenin signalling occurred in the cell lines, which is in discrepancy with results from primary
CLL. However, treatment with 5-aza-2´-deoxycytidine caused accumulation of β-catenin. Simultaneously, E-cadherin
expression was strongly induced, leading to the formation of a complex with β-catenin and thus demonstrating its
epigenetically regulated inhibition effect.
Conclusions: The results suggest an epigenetic silencing mechanism of the Wnt/β-catenin pathway inhibitor genes
in CLL. Hypermethylation and silencing of functionally related genes may not be completely stochastic but result
from the tumour epigenome reprogramming orchestrated by Polycomb-group repressive complexes. The data are
of interest in the context of epigenetic-based therapy.
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Constitutive Wnt/β-catenin signalling is increasingly
recognised to be a vital ingredient for the malignant
phenotype of different types of tumours including the
most common haematological malignancy, B cell chronic
lymphocytic leukaemia (CLL) [1-4]. The Wnt pathway is
indispensable for normal embryonic development and
cell differentiation, including that of the B cell lineage
[5]. Being dormant in normal peripheral B-lymphocytes
[3], the Wnt pathway is aberrantly activated in CLL and
contributes substantially to the anti-apoptotic and mito-
genic characteristics of CLL B cells [1,3,6]. Inhibition of
key pathway components suppresses survival of CLL B
cells ex vivo and in a xenograft model [1,6,7]. Therefore,
the mechanisms underlying aberrant functioning of the
Wnt pathway are of considerable therapeutic interest. In
addition, the recent finding of active Wnt/β-catenin sig-
nalling in the pre-leukemic state of monoclonal B cell
lymphocytosis could suggest the potential of CLL pre-
vention by targeting the pathway early during the devel-
opment of CLL [3].
The Wnt pathway operates by stabilising the key
downstream effector β-catenin in the cytoplasm [8].
In the non-activated state of the pathway, cytoplasmic
β-catenin undergoes constant N-terminal phosphoryl-
ation at the residues S33, S37, T41 and S45, which
act as covalent marks for proteasomal degradation [2].
Pathway activation occurs upon binding of the growth
factors of the Wnt class to the membrane receptors
of the Frizzled family (FZD) and prevents β-catenin
from being degraded. As a consequence, its translocation
to the nucleus is promoted, where it forms a transcrip-
tionally active complex with the members of the T-cell
factor/lymphocyte enhancer factor (TCF/LEF) family of
transcription factors and induces the expression of pro-
survival and proliferative genes (e.g., cyclin D, c-myc) [8].
Signal transduction is negatively controlled by multiple
physiological inhibitors. These belong to several protein
families and operate at different points along the path-
way. Secreted frizzled-related proteins 1 to 5, DKK1 to 4
and WIF1 prevent the induction of signalling by interfer-
ing with the upstream components on the cell surface,
namely the Frizzled receptor and the LRP5-6 co-receptor
[8]; DACT1 induces degradation of the cytoplasmic ef-
fector Dishevelled [9]; the adhesion molecule E-cadherin
(CDH1) directly binds β-catenin on the cellular mem-
brane, thereby sequestering it from the cytoplasm [10].
The mechanism of the aberrant functioning of the
Wnt/β-catenin pathway in CLL remains only incom-
pletely understood [1]. Some data suggest that at least
partially it may rely on the epigenetic silencing of path-
way inhibitors. Aberrant hypermethylation of some an-
tagonistically active genes has been reported as a
mechanism for pathway induction in several types ofsolid tumours [11-13]. Additionally, for a variety of
human malignancies, there is growing evidence that an
epigenetic inactivation of the Wnt/β-catenin pathway
inhibitors is associated with a tumour-favourable pheno-
typic outcome [14]. Little is known, however, about the
functional relevance to CLL. The current knowledge is
largely limited to the qualitative description of the
methylation status of individual genes in patient material.
Aberrant hypermethylation and its role in the loss of ex-
pression have been shown for some SFRP family mem-
bers [15-18] but there are only fragmentary data about
the methylation status of the other Wnt/β-catenin
antagonists in CLL [15,17,19].
Using specialised oligonucleotide microarrays, we had
identified aberrant promoter methylation of DKK2 and
DKK3 and confirmed earlier findings for SFRP1, SFRP2
and SFRP4 [16] on a limited number of primary CLL
samples (unpublished data). This led us to formulating
the hypothesis that the different inhibitors of the Wnt/β-
catenin pathway may undergo concordant aberrant
hypermethylation in malignant B cells, thereby contribut-
ing to the development of CLL. In this study, we investi-
gated systematically and quantitatively the methylation
status and the expression of the genes of twelve Wnt/β-
catenin pathway inhibitors in two CLL cell line models
and primary CLL B cells. We found a strong association
of hypermethylation and transcriptional regulation of the
antagonists in CLL. In addition, protein analyses revealed
that no constitutive expression of ß-catenin occurred in
the cell lines, as opposed to results from primary CLL.
However, treatment with 5-aza-2´-deoxycytidine restored
β-catenin expression. As a confirmation that variation of
methylation is not just directly regulating the expression
of ß-catenin while the variations in the antagonist genes
are coincidental but functionally irrelevant, we also stud-
ied the protein expression and functioning of the antag-
onist factor adhesion molecule E-cadherin (CDH1) upon
pharmacologically induced DNA demethylation.
Methods
Cell culture, drug treatment and patient samples
The chronic lymphocytic leukaemia cell lines MEC-1
[20] and EHEB [21] were obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany) and were grown in a medium
consisting of 90% Iscove's Modified Dulbecco's Medium
(Invitrogen, San Diego, USA) or Roswell Park Memorial
Institute Medium (Invitrogen), respectively, supplemen-
ted with 10% foetal bovine serum (Invitrogen). Treat-
ment of cells with 5-aza-2´-deoxycytidine (5-aza-dC;
Merck Chemicals, Nottingham, UK) was performed for
72 h and 96 h, starting cultures from 5 × 105 cells/ml.
For the 96 h-treatment, the medium was changed after
48 h in order to supply fresh drug. Since a treatment
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of methylation of hypermethylated genes (on average by
9.5%), further experiments were performed at higher
drug concentrations (1.0 and 2.0 μM), which did not
affect the per cent of viable cells in cultures (>90%) as
shown with Vi-Cell Automated Cell Viability Analyzer
(Beckman Coulter, Brea, USA). These 5-aza-dC concen-
trations, but not lower doses, proved to be effective in
DNMT1 depletion and transcriptional reactivation of dif-
ferent genes in CLL cell line WaC3CD5 in an earlier
study [22] as well as in other cell lines of B cell lineage
[23,24].
Peripheral blood was obtained from 12 patients of
Volgograd Regional Clinical Oncological Dispensary
No.1 (Volgograd, Russia) and the National Haematology
Research Centre of the Russian Academy of Medical
Sciences (Moscow, Russia). Written informed consent
was given and the experiments were approved by the in-
stitutional Ethical Review Boards. Diagnosis of CLL was
established according to standard morphologic and
immunophenotypic criteria [25]. All patients were un-
treated at the time of blood collection. Peripheral blood
mononuclear cells were isolated by a standard procedure
using Ficoll-Hypaque gradient centrifugation as
described elsewhere [26]. A total of five buffy-coats from
the peripheral blood of healthy individuals were pro-
vided by the Institute for Clinical Transfusion Medicine
and Cell Therapy (Heidelberg, Germany). CD19+ cells
were isolated from control samples using Dynabeads
CD19 pan B (Invitrogen, Carlsbad, USA) according to
the manufacturer’s protocol and employed as a refer-
ence. The cells were collected and snap-frozen for the
subsequent extraction of nucleic acids. The patient data
are summarised in Additional file 1: Table S1.
DNA isolation and bisulphite conversion
DNA was extracted from the samples using the QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany) as sug-
gested by the manufacturer. DNA concentration was
measured in a ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, USA). A total of 1.9 μg DNA
was treated with sodium bisulphite using the EpiTect
Bisulfite kit (Qiagen). The efficiency of bisulphite con-
version averaged 98.8% and was computed from the
sequences of 231 cloned PCR-products of CDH1,
DACT1, DKK1, DKK2, DKK3, DKK4, SFRP1, SFRP2,
SFRP3, SFRP4, SFRP5 and WIF1 using the BISMA soft-
ware, which considers the non-CpG cytosines within the
sequences [27].
PCR amplification
PCR-amplification of the loci interrogated was carried
out in 25 μl reactions that contained 2.0 μl bisulphite-
converted DNA, 1.5 mM MgCl2, 125 mM dNTP, 200 nMprimers, 0.65 units HotStar Taq DNA polymerase and 1x
Q-solution (Qiagen). A previously reported amplification
protocol was employed [28]. Briefly, amplification was
started by an initial activation of the HotStar Taq DNA
polymerase at 95°C for 15 min. The first amplification
cycle was denaturation at 95°C for 1 min, annealing at
62°C for 2 min and elongation at 72°C for 3 min. This
procedure was continued for 20 cycles, reducing the
annealing temperature by 0.5°C each cycle, followed by
25 cycles of 1 min denaturation at 95°C, 2 min annealing
at 52°C and 2 min elongation at 72°C. The sequences of
the PCR primers are listed in Table 1. About 5 μl of each
reaction was examined on 2% agarose gels.
In order to control for possible amplification bias, ap-
propriate calibration was performed as described in de-
tail [28]. Fully methylated and unmethylated human
control DNA that had been bisulphite-treated was pur-
chased (EpiTect PCR control DNA; Qiagen) and mixed
in different ratios to obtain calibration samples that rep-
resent distinct methylation percentages of 0, 12.5, 25,
37.5, 50, 62.5, 75, 87.5 and 100%, respectively. A total of
15 ng calibration DNA was used for the amplification of
each locus.
Bisulphite pyrosequencing
A volume of 20 μl of each PCR product was mixed with
2 μl Streptavidin Sepharose High Performance (GE
Healthcare, Uppsala, Sweden), 38 μl PyroMark binding
buffer (Qiagen) and 20 μl water. The Vacuum Prep
Workstation (Biotage, Uppsala, Sweden) was used to
prepare single-stranded DNA according to the manu-
facturer’s instructions. The Sepharose beads with the
single-stranded templates attached were released into a
PSQ 96 Plate Low (Biotage) containing 15 μl of 0.6 μM
corresponding sequencing primer in annealing buffer.
Pyrosequencing reactions were carried using the Pyro
Gold Reagent Kit (Biotage) in a PSQ HS 96 Pyrosequen-
cing System (Biotage) according to the manufacturer’s
protocol. The sequences of the pyrosequencing primers
are listed in Table 1. Quantification of CpG methylation
was performed using the Software PyroQ-CpG v.1.0.9
(Biotage). The initial amplification result containing a
bias towards unmethylated alleles was corrected using
the calibration data derived from the control samples as
previously described [28]. The PCR-product of SFRP1
was sequenced directly using Sanger chemistry. Despite
optimisation efforts, accurate quantification was not pos-
sible by alternative pyrosequencing assays, which resulted
either in enormous bias towards the methylated allele or
readouts with lack of specificity.
Bisulphite Sanger sequencing
The PCR products were purified with the QIAquick
PCR Purification kit (Qiagen) and cloned using the
Table 1 Sequences of the PCR and pyrosequencing primers used in this study
Gene symbol Primer sequences (5´-3´) *
F: PCR forward; R: PCR reverse;







CDH1-F TTTTTTTTGATTTTAGGTTTTAGTGAG 421 [29]
CDH1-R bio-ACTCCAAAAACCCATAACTAACC
CDH1-S AGTTAGTTTAGATTTTAGTT 9 this study
DACT1-F GTTTGGGAAGTGAAAGAAATTTAATT 184 [30]
DACT1-R bio-CTAAAACCCCAACATCCTATTACAAT
DACT1-S AGATTGTGTTGTAATTTGGT 5 this study
DKK1-F bio-GGGGTGAAGAGTGTTAAAGGTT 326 [31]
DKK1-R AAACCATCATCTCAAAAAAACTCAA
DKK1-S CTACAAAAAACACAAAACTCTAC 8 this study
DKK2-F bio-TTTTAGTAGTTGTGGGTGGAGATA 456 this study
DKK2-R ATACTCCTTTTCAAAATTAACAAAC
DKK2-S CCTAACTCACAAAAAACAAC 11
DKK3-F GATTTTGTTGAGTTTAGTTTTTTTTGGT 123 [32]
DKK3-R bio-CAAACCTCTCTCAACCCCTACCTA
DKK3-S TTTTTTGGTGGATGTG 5 this study
DKK4-F bio-ATAGATTTGAAGGGATTTGTTGAAGTTT 328 [33]
DKK4-R CAAAACCAACTCAACCCCAACAAAAC
DKK4-S CTAAACTAACAACTCAACAC 2 this study
SFRP1-F TTTTTAAGGGGTGTTGAGT 412 [16]
SFRP1-R CAAACTTCCAAAAACCTCC
SFRP1-S GGAGTTGATTGGTTG (Sanger sequencing) this study
SFRP2-F ATGTTTGGTAATTTAGTAGAAATTT 409 this study
SFRP2-R bio-CAACCAAAATTTTCTTAACCTTTTT
SFRP2-S GATTGGGGTAAAATAAGTT 14
SFRP3-F bio-GTGATTTAGGGGAGGAGATATTTTAGA 542 this study
SFRP3-R TTCCAAAACAAAAACTTACACAAAA
SFRP3-S CAAAATAAAACAAAATACAAC 4
SFRP4-F bio-GTGTTTTGTGTGTTAGA 220 [16]
SFRP4-R CCACTAAAATAAAAAAAAACATAACA
SFRP4-S TACCACCCTCATCTTTC 2 this study
SFRP5-F GTAGGGAGTTTTGGGGAGAAA 272 [16]
SFRP5-R bio-CCCAAATAAATAACAACCTAC
SFRP5-S GTTTTGGAGTTGGGGTTAG 8 this study
WIF1-F bio-GAGTGATGTTTTAGGGGTTT 414 [34]
WIF1-R CCTAAATACCAAAAAACCTAC
WIF1-S AAACTACATTCACAATAC 7 this study
* Primers of the same sequence but without biotin modification were employed for amplification of the PCR-products used for subcloning and bisulphite
sequencing.
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at random and sequenced with Sanger chemistry at
GATC Biotech (Constance, Germany). The sequencing
data were visualised using the CpGviewer software [35].Statistical analysis
For each locus, the average methylation percentage
across the interrogated CpG sites was calculated. Differ-
ences observed between the patient and control groups
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[36]. As the country of origin (Russia or Germany), sex,
and age of the probands might have been influential cov-
ariates, they were taken into account. Thus, we fitted the










are the methylation measurements
that were square root-transformed to achieve normality;
β0 is the model intercept; β1 is the effect of the country
of origin, which is used as a binary variable that takes
value 0 for Germany and 1 for Russia; β2 is the effect of
the proband’s status (a binary variable 0 for healthy and
1 for a diseased individual); β3 is the effect of sex (0 for
a female and 1 for a male individual); β4 is the effect of
age, and E represents the model residuals. Ideally, model
residuals should be normally distributed with mean 0
and a certain constant variance. However, an exploratory
analysis revealed high variation of methylation between
the countries as well as between the healthy and dis-
eased individuals. The homogeneity of variance assump-
tion was thus relaxed by allowing the variance to be
different in each stratum, i.e. in each of the combina-
tions of country and disease status [36].
The full model was then reduced by stepwise back-
ward elimination of insignificant terms. For each gene,
only the final optimal model found by this approach is
reported. Validation of the optimal models was per-
formed by an examination of the quantile-quantile plots
of their residuals [36]. Estimation of the model para-
meters was conducted based on the restricted maximum
log-likelihood algorithm using the nlme v3.1-102 pack-
age [37] for the R computing environment [38]. P-values
of less than 0.05 were regarded as statistically significant.
RNA extraction and quantitative RT-PCR
Total RNA was isolated using the miRNeasy Mini Kit
(Qiagen) as suggested by the manufacturer. The RNA
concentration was measured in a ND-1000 spectropho-
tometer (Thermo Scientific). The quality of the RNA
samples was confirmed in a 2100 Bioanalyzer (Agilent,
Santa Clara, CA). The RNA integrity number [39] of the
samples averaged 9.7. Reverse transcription reactions
were carried out with 1 μg of total RNA using Super-
Script III Reverse Transcriptase (Invitrogen) and 0.5 μg
oligo(dT) 12–18 primer (Invitrogen). Quantitative RT-
PCR was performed in triplicate with the ABI PRISM
7900 Sequence Detection System (ABI, Foster City,
USA) using the Absolute QPCR SYBR Green mix
(Thermo Scientific). The identity codes of the commer-
cially available PCR-primers are as follows:
Hs_CDH1_1_SG, Hs_DACT1_2_SG, Hs_DKK1_1_SG,Hs_DKK2_1_SG, Hs_DKK4_1_SG, Hs_SFRP1_1_SG,
Hs_SFRP2_1_SG, Hs_FRZB_2_SG, Hs_SFRP4_3_SG,
Hs_WIF-_1_SG, Hs_GAPDH_1_SG (Qiagen), DKK3-
qRTF1 and DKK3-qRTR1 (Thermo Scientific). Primer
sequences for SFRP5 have been reported earlier:
5´-CTGACGGCCTCATGGAGCAGATGT-3´ (forward)
and 5´-TCCAATCAGCTTCCGG TCCCCATT-3´ (re-
verse) [16]. Universal Human Reference (UHR) total
RNA was used as a calibration control (Stratagene, La
Jolla, USA). The calibration graph (ct vs. log unit of the
standard template) was obtained as described [40]. Two
housekeeping genes – glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and β-actin (ACTB) – were
tested. GAPDH was superior over ACTB exhibiting only
minor variation of expression in all studied conditions
(CV 10.4% vs. 34.9%, respectively) and therefore served
as an internal control. The thermal cycler conditions
were as follows: 50°C for 2 min and 95°C for 15 min, fol-
lowed by a two-step PCR of 45 cycles at 95°C for 15 sec
and 60°C for 60 sec.
Quantification of E-cadherin and β-catenin expression
For protein extraction, cells were lysed shaking at 4°C for
30 min in a buffer containing 50 mM Tris/HCl (pH 7.4),
150 mM NaCl, 1% Triton X-100, 1x Complete Protease
Inhibitor (Roche Diagnostics, Mannheim, Germany), 1x
phosphatase inhibitor I and III (Sigma-Aldrich, St. Louis,
USA) and 2.5 U/ml benzonase (Qiagen). Cells were
passed through a 25 gauge needle, and cell debris was
removed by centrifugation at 15,000 g for 30 min at 4°C.
Protein quantification was performed by an immuno-
assay as previously described [41]. An antibody that is
specific for the C-terminus of β-catenin (BD Biosciences,
Franklin Lakes, USA) was covalently immobilised on
magnetic xMAP microspheres (Luminex, Austin, Texas)
[42]. Per well of a microtiter plate (non-binding surface;
Corning, New York, USA), 2,000 beads in 20 μl blocking
reagent for ELISA (Roche Diagnostics) were incubated
with 20 μg protein from cell lysates in 40 μl with lysis
buffer. In calibration experiments, defined amounts of
recombinantly expressed GST-β-catenin were used. In-
cubation was overnight at 4°C. The samples were trans-
ferred to a blocked filter plate (Millipore, Billerica, USA)
and washed twice with 100 μl PBS using a vacuum
manifold (Millipore). For detection, 30 μl of anti total β-
catenin antibody (Invitrogen; 1:200 diluted in the assay
buffer) were added to the beads. Incubation was at room
temperature for 120 min. Unbound antibody was
removed by washing with PBS as described above. A vol-
ume of 30 μl of 2.5 μg/ml donkey anti-rabbit phyco-
erythrin-conjugated antibody (Jackson ImmunoResearch,
West Grove, USA) was added next and incubated for
45 min at room temperature. After another washing
with PBS, the beads were resuspended in 100 μl assay
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(Luminex Corp, Austin, USA). Calculation of the abso-
lute β-catenin expression was based on a seven-point di-
lution series of the recombinant standard protein.
For the quantification of E-cadherin, an E-cadherin-
specific antibody (R&D Systems, Minneapolis, USA) was
employed as the bead-bound capture reagent. All dilu-
tion, incubation, washing and measurement steps were
performed as described above. However, the detection
system consisted of biotinylated detection antibodies
specific for E-cadherin (R&D Systems) and phycoerythrin-
conjugatedLeandro,USA).RecombinanthumanE-cadherin
Fc Chimera (R&D Systems) was used as standard.
Results
Wnt/β-catenin pathway inhibitor genes are concurrently
hypermethylated both in CLL cell lines and patient
samples
To find out if the expression of the Wnt/β-catenin path-
way inhibitors may be regulated by DNA methylation,
the two CLL cell lines EHEB and MEC-1 were studied.
First, bisulphite pyrosequencing was performed to exam-
ine the methylation status of twelve inhibitor genes. After
correction of the raw data for PCR-bias and artificial var-
iations introduced by the pyrosequencing process as
described [28], accurate quantification of the methylation
degree was performed for CpG dinucleotides that are
located in proximity to the transcriptional start sites or
those associated with expression down-regulation of the
respective genes in solid tumours [30,34] (Figure 1A). A
high degree of methylation was recorded (average methy-
lation percentage in EHEB/average methylation percent-
age in MEC-1) for CDH1 (79/79), DKK1 (68/75), DKK2
(88/83), SFRP3 (94/71) and WIF1 (71 in EHEB). Partial
methylation was observed for DKK3 (23/37), DKK4 (31
in EHEB), SFRP2 (32/17) and SFRP4 (24/29). The genes
DACT1 (10/0), SFRP5 (14/6), DKK4 (9 in MEC-1) and
WIF1 (11 in MEC-1) were essentially unmethylated.
Pyrosequencing of SFRP1 failed, although various pri-
mers were tested. However, extensive hypermethylation
of SFRP1 in both cell lines was confirmed by semi-
quantitative bisulphite Sanger sequencing. Overall, ten
out of twelve antagonists of Wnt/β-catenin signalling
exhibited substantial methylation of the gene in at
least one of the two CLL cell line models.
Because DNA methylation in established cancer cell
lines may not always adequately reflect the reality in pri-
mary tumours, also patient and control samples were
studied for confirmation (Figure 1B). Consistent with
the observations in the cell lines, eleven genes were
found to be at least partially methylated in the patient
material (average methylation percentage across twelve
patient samples; lowest and highest value): CDH1 (56;
22 to 88), DKK1 (34; 17 to 84), DKK2 (35; 14 to 78),DKK3 (18; 5 to 61), DKK4 (32; 0 to 71), SFRP2 (21; 2 to
70), SFRP3 (26; 6 to 50), SFRP4 (17; 3 to 68), SFRP5 (15;
6 to 27), WIF-1 (30; 8 to 73). Again, extensive hyper-
methylation of SFRP1 was shown by semiquantitative
bisulphite Sanger sequencing. In contrast, and in accord-
ance with the cell line data, DACT1 was basically
unmethylated (2; 1 to 5) in all samples. All the loci inter-
rogated were essentially unmethylated in control CD19+
B cells of five healthy individuals with the exception of
DKK4, which was found to be methylated (36; 33 to 39)
to a level very similar to that in the cancer samples.
The methylation patterns of most genes were hetero-
geneous within the patient group. However, the levels of
methylation for CDH1, DKK1, DKK2, DKK3, SFRP3 and
WIF1 were significantly higher than in the control group
(Figure 2). Although there was no statistically significant
difference between the patient and control groups for
the other genes, abnormally high methylation – defined
as an increase of the average methylation level beyond
that of the average observed in the group of normal
tissues plus twice the standard deviation [43] – was a
frequent event in patient CLL samples but for DACT1
and DKK4.
To exclude a possible contribution of additional cov-
ariates such as country of origin, sex or age of the indivi-
duals to the observed alterations of DNA methylation,
we took them into account by using generalised least
squares models. A disease-specific nature of methylation
differences between compared groups was confirmed for
all the genes, which exhibited differential methylation
between the groups [see Additional file 2: Table S2]. The
results obtained from bisulphite pyrosequencing were
validated by genomic bisulphite Sanger sequencing of
randomly cloned PCR-products (Figure 3). The data
obtained were in full agreement with the results of the
pyrosequencing assay. In combination, the sequencing
results indicate that the genes of most Wnt/β-catenin
pathway inhibitors are prone to aberrantly high methyla-
tion in CLL.
Expression of the wnt/β-catenin pathway inhibitors is
associated with the methylation status
In order to ascertain the role of methylation in the
regulation of expression, mRNA levels of the twelve
genes were analysed by quantitative PCR in the cell
lines EHEB and MEC-1 after treatment with 5-aza-
2´deoxycytidine (5-aza-dC). Incorporation of this nucleo-
side analogue into DNA is known to capture covalently
DNA methyltransferases, thereby inducing DNA hypo-
methylation [44]. At a concentration of 1.0 and 2.0 μM,
the drug induced on average a 25% decrease in the
methylation level of the strongly methylated genes
(Figure 4A). This decrease in DNA methylation was as-
sociated with a significant transcriptional re-activation
Figure 1 Maps of the studied sequences. (A) Schematic representations of the genomic regions are shown. The gene names and the
chromosomal locations are given. Vertical bars indicate the positions of CpG dinucleotides. Exons are shown above as black rectangles; arrows
indicate the known or presumed transcriptional start sites. Red bars below specify the regions analysed by bisulphite pyrosequencing; blues bars
indicate the area studied with bisulphite Sanger sequencing; the magenta bar shows the region studied by direct bisulphite sequencing of the
SFRP1 PCR-product. (B) Methylation patterns of the Wnt/β-catenin pathway inhibitor genes. Each square represents a CpG site. The degree of
methylation was measured by bisulphite pyrosequencing in the EHEB and MEC-1 cell lines, in 12 patient samples (CLL1 to CLL12) and CD19+ B
cells from healthy donors. At the bottom, an intensity scale is shown. Results for SFRP1 were obtained by direct Sanger sequencing of the
respective amplicon.
Figure 2 Methylation of the inhibitor genes in patient CLL samples. Methylation in tumour cells (filled circles) and control CD19+ B cells
(empty circles) were analysed by bisulphite pyrosequencing. Each circle indicates the methylation degree of a particular sample. Horizontal bars
denote the median methylation level for the patient group or the healthy donors, respectively.
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Figure 3 Results of Sanger bisulphite sequencing of patient and control samples. For each gene, DNA of the patient with the maximal
methylation within the group of twelve (top) and one with an average degree of methylation (middle) were analysed. Also the result of one
randomly selected control (CD19+) is shown (bottom). Every row of circles represents the CpG sites of an individual clone. The density of the CpG
sites in the genomic sequence is represented by the distances between the circles. Open and filled circles stand for unmethylated and
methylated CpG sites, respectively. Grey circles denote point mutations found in SFRP5 (CLL6, CLL9, CD19+). Horizontal lines above the circles
labelled with “PYRO” indicate the regions quantified by bisulphite pyrosequencing. Arrows indicate the positions of known or presumed
transcriptional start sites.
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http://www.biomedcentral.com/1471-2407/12/213of CDH1, DKK3, DKK4, SFRP2, SFRP3, SFRP4 and
WIF1 in at least one of the two cell lines (Figure 4B).
It is interesting to note that the expression of SFRP3
was induced 13.5- and 9.1-fold in EHEB and MEC-1, al-
though no CpG island has been annotated from the gen-
omic sequence [16]. This fact may highlight the rather
artificial character of CpG island definition. The effect of
the methylation decrease on expression was striking,which may actually be particularly due to the small num-
ber of CpG sites in the region (although some indirect
activation mechanism cannot be excluded either). DKK1,
DKK2 and SFRP1 were also highly methylated in both
cell lines. Still, treatment with 5-aza-dC did not result in
a significant induction of expression, although methyla-
tion was reduced to a degree that was similar to that of
SFRP3. The genes DKK1, DKK2 and SFRP1 do have CpG
Figure 4 Quantification of methylation degrees and expression of the inhibitor genes in CLL cell lines EHEB and MEC-1 upon
treatment with 5-aza-dC. (A) The average percentage of methylation was recorded by bisulphite pyrosequencing after 72 h growth in pure
medium (deep blue bars) and in presence of 1.0 or 2.0 μM 5-aza-dC (intermediate and light blue bars), respectively. (B) Quantification of mRNA
expression levels by PCR. As in panel A, control and experimental conditions are represented by different shades of red. Three separate
measurements were performed for each sample. GAPDH was used as an internal control. The expression in untreated cells was set to 1.
Significant induction of mRNA expression in both or one cell line is indicated with ** or * at the bottom.
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http://www.biomedcentral.com/1471-2407/12/213islands in their sequences. Apparently, the demethylation
effect was too little or insufficient on its own to change
the overall blockage of expression.
Expression of DACT1 exhibited yet another, very con-
trasting result. It was substantially up-regulated after in-
cubation with 5-aza-dC (10.5-fold and 3.5-fold in EHEB
and MEC-1, respectively), even though the gene was es-
sentially unmethylated even prior to the treatment. This
clearly indicates an indirect control of this gene’s activity
by the variation of the degree of DNA methylation; its
own sequence is not affected, however.
Upon 5-aza-dC treatment, CLL cell lines accumulate
β-catenin that binds to the induced E-cadherin
In order to demonstrate the functional relevance of epi-
genetic control of antagonists to the overall regulation
of the Wnt/β-catenin pathway, we looked at the vari-
ation in the amounts of transcriptionally active (non-
phosphorylated) β-catenin and E-cadherin in EHEB and
MEC-1 cell lines. The amount of non-phosphorylated
β-catenin correlates directly with the activity of the
pathway. For this analysis, we took advantage of suspen-
sion bead arrays, which had already been used for the
detection of different cytoplasmic fractions of β-catenin
[41]. No constitutive Wnt/β-catenin signalling could bedetected in the cell lines. The non-phosphorylated frac-
tion of β-catenin was hardly detectable (data not shown)
at either condition, suggesting dormancy of this path-
way route or a very efficient degradation process. How-
ever, the β-catenin level strongly increased in cell lysates
after a treatment of the cells with 2.0 μM 5-aza-dC for
72 h and 96 h (Figure 5A), indicating a methylation con-
trolled silencing in cell lines. Concomitantly to the in-
crease in β-catenin levels, also the amount of E-cadherin
increased substantially upon CDH1 hypomethylation,
while the protein was basically undetectable under con-
trol conditions (Figure 5A). As expected, β-catenin and
E-cadherin formed a complex, which as a result of the
higher expression levels of CDH1 was also present at
much higher concentrations after treatment with 5-aza-
dC (Figure 5C).
Discussion
Aberrant activation of the Wnt/β-catenin pathway in
primary CLL is known to contribute to the defect in
apoptosis inherent to this malignancy [3,6,7,17]. Differ-
ent molecular mechanisms for this were suggested, in-
cluding the autocrine activation by the overexpressed
Wnt ligands [7], silencing of E-cadherin due to aberrant
splicing [45] or epigenetic down-regulation of pathway
Figure 5 Quantification of the amounts of β-catenin, E-cadherin
and the E-cadherin/β-catenin complex in the cell lines EHEB
(blue bars) and MEC-1 (red bars). The amount of β-catenin (A),
E-cadherin (B) or the E-cadherin/β-catenin complex (C) was
determined after 72 h and 96 h cell growth in presence (+) or
absence (−) of 2.0 μM 5-aza-dC. The measurements without 5-aza-
dC shown in panels (A) and (B) produced only residual signal
intensities.
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lated by the findings of aberrantly methylated CDH1
[19] and SFRPs [16] as well as our own evidence on
hypermethylation of DKK2 and DKK3 in primary CLL,
we quantitatively characterised the methylation status
and the expression of the Wnt/β-catenin pathway inhibi-
tors. Ten of the twelve genes exhibited high DNA
methylation in at least one of the CLL cell lines and also
in patient samples compared to non-tumour material.
The absolute level of methylation, however, varied
strongly between the genes.By far the biggest difference in methylation between
tumour and normal could be seen for SFRP1, which was
hypermethylated in all tumour samples. Surprisingly,
however, the apparent change in transcript level upon
DNA demethylation with 2 μM 5-aza-dC was insignifi-
cant. In contrast, methylation in the promoter regions of
DACT1 and DKK4 did not differ between tumour and
normal. However, their transcription was affected by
changes to the degree of DNA methylation, although for
DACT1 this happened clearly indirectly via a yet un-
known factor. The fact that DNA methylation was found
to be involved in the regulation of the antagonist genes’
expression in the cell lines and the close similarity of the
methylation patterns to those of primary CLL B cells
suggests the existence of an epigenetic silencing mech-
anism in this haematological malignancy.
Owing to the absence of the CpG island within its 5´
region, SFRP3 was the only member of the SFRP class,
whose methylation status had not been analysed in most
of reports published earlier, irrespective of the studied
tumour type. However, we could demonstrate that hyper-
methylation of CpG sites in the first exon was associated
with an apparent transcriptional down-regulation to an
extent that was well beyond that seen for other genes.
Also overall, the variation of methylation upon addition
of the demethylation agent differed between genes. There
might be a correlation between the intensity of the effect
observed and the mere number of CpG sites or their fre-
quency in a given stretch of DNA sequence. However,
the data set from this study was too small for any signifi-
cant evaluation and more quantitative analyses are
required to proof an actual relationship.
Also, the degree of demethylation induced by 5-aza-
dC had different apparent effects on the transcription
levels. The extent of variation may be controlled by the
sequences next to the CpG sites. Such an effect is known
for the formation of left-helical Z-DNA structures,
which are most likely to occur in methylated d(CG)
sequences [46]. A conformational twist from right- to
left-helical secondary structure can occur from one base
to the next and back, resulting in a net structural vari-
ation that only disturbs or relaxes the right-turning helix
rather than inducing a strong conformational change.
This variation in the structural components of a se-
quence could explain an associated variation in gene ac-
tivity and could topologically affect also DNA stretches
that have some distance from the actual CpG site.
Because epigenetic down-regulation of the Wnt/β-
catenin pathway inhibitors may be instrumental in the
constitutive Wnt/β-catenin signalling in primary CLL
[3,6,7,17], we wondered if the pathway is active in the
CLL cell lines and can be modulated upon DNA hypo-
methylation. However, no constitutive Wnt/β-catenin
signalling could be detected in either of the two cell
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tive β-catenin fraction. This obvious discrepancy with
primary CLL [3,7] might reflect a secondary loss of the
constitutively active pathway in the established cell
lines. This observation is in agreement with a recent re-
port [6], which has documented much less β-catenin
and lymphoid enhancer-binding factor 1 (LEF-1, a dir-
ect target of the pathway [47]) in the CLL cell lines
JVM-1 and MEC-1 in comparison with the patient sam-
ples. Given a dormant Wnt/β-catenin pathway in the
CLL cell line models, it was therefore not possible to
ascertain, if pharmacological restoration of all the path-
way antagonists can affect its activity. Nevertheless, the
role of epigenetic silencing of one of the inhibitors,
E-cadherin, could be demonstrated. We showed that its
expression is regulated by promoter methylation both
on transcriptional and protein levels. Significantly up-
regulated upon 5-aza-dC treatment, E-cadherin binds
β-catenin thereby capturing it on the cellular membrane.
We speculate that epigenetic restoration of E-cadherin
expression in the cells with aberrantly active Wnt/β-
catenin signalling might suppress it in a similar way as
the enforced E-cadherin expression in the primary CLL
B cells lead to down-regulation of the pathway [45].
Thus, this finding may be of therapeutic interest.
Finally, observations from this study draw attention to
two aspects, which warrant further clarification. First, the
concurrent hypermethylation and silencing was shown
for the genes of a single pathway, which are located on
different chromosomes. This finding may support a
model of carcinogenesis suggested earlier, in which epi-
genetic silencing is not completely stochastic but might
reflect the existence of a directed program, by which
functionally related groups of genes important for devel-
opment of tumours are silenced through promoter
methylation [48]. Our data may add further evidence for
such a guiding role of Polycomb-group repressive com-
plexes (PRC) in patterning aberrant DNA hypermethyla-
tion in cancer. These epigenetic regulatory proteins
induce repressive chromatin states by covalently modify-
ing histones (H3K27me3) within promoters of many de-
velopmentally regulated genes in embryonic and adult
stem cells [49,50]. Also in B cells, a PRC2 component
EZH2 was shown to contribute to epigenetic reprogram-
ming of naïve B cells as they transit through germinal
centre, which may facilitate proliferation and lymphoma-
genesis [51]. Given the facts that (1) promoter regions of
the Wnt pathway antagonists are repressively marked
with H3K27me3 in either naïve B cells, centroblasts or
embryonic stem cells [51,52], (2) promoters of DKK1,
DKK2, SFRP1 and SFRP2 are occupied with the PRC2
component EZH2 in these cells, (3) recruitment of DNA
methyltransferases by EZH2 [53] and (4) age dependent
aberrant hypermethylation of PRC targets [54] have beenreported, it is plausible to assume that concurrent hyper-
methylation of specific groups of genes is an interrelated
part of general epigenome reprogramming orchestrated
by PRC.
Second, despite the fact that cancer-associated CpG
hypermethylation has been shown early in development
of solid tumours [55], nothing is known about epigenetic
alterations in a CLL precursor state monoclonal B cell
lymphocytosis (MBL) [56]. However, up-regulation of
LEF-1, a direct target of the Wnt pathway and a pro-
survival factor, has recently been reported in MBL
patients, who are known to be at risk for progression to
CLL [3]. Therefore, deregulation of the Wnt/β-catenin
pathway may have a role in CLL leukaemogenesis and
further methylation analysis of the antagonists in MBL is
desirable in view of possible benefits for CLL prevention
by DNA demethylating drugs, if epigenetic aberration of
these genes is detected at an early stage of MBL.
Conclusions
Our results show concurrent hypermethylation of mul-
tiple Wnt/β-catenin pathway inhibitor genes in CLL. The
methylation status is associated with expression, what
suggests epigenetic silencing mechanism of this signal-
ling route. Aberrant hypermethylation of the whole
group of functionally related genes may not be com-
pletely stochastic but result from the epigenome repro-
gramming orchestrated by Polycomb-group repressive
complexes. The data are of interest in the context of
epigenetic-based therapy.
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